MAPT and Alzheimer disease: Treatment of young human tau (htau) and P301L tau JNPL3 mouse models of tauopathy, representing tau aggregation in AD and 4R tauopathies mice from 3 to 7 months of age prevented the accumulation of tau aggregates (Davidowitz et al. 2023, 2020).